Virginia Arechavala‐Gomeza

Ikerbasque — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

27h-index4.0kcitations73works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Muscle Physiology and Disorders(50), RNA Interference and Gene Delivery(14), Neurogenetic and Muscular Disorders Research(13), RNA Research and Splicing(9), Virus-based gene therapy research(9)

Publications73 total

The current and future landscape of RNA-based therapies and diagnostics
Communications Medicine·2025Open Access
Ending publication bias: A values-based approach to surface null and negative results
PLoS Biology·2025· 3 citedOpen Access
Characterization of <i>DMPK</i> and MBNL1 expression in cell models of myotonic dystrophy: a platform for drug screening
NAR Molecular Medicine·2025· 1 citedOpen Access
Collablots: Quantification of Collagen VI Levels and Its Structural Disorganisation in Cell Cultures From Patients With Collagen VI‐Related Dystrophies
Neuropathology and Applied Neurobiology·2025Open Access
Antisense RNA therapies for muscular dystrophies
Journal of Neuromuscular Diseases·2025· 9 citedOpen Access
Characterisation of <i>DMPK</i> and MBNL1 expression in cell models of Myotonic Dystrophy: A platform for drug screening
2025
Collablots: Quantification of collagen VI levels and its structural disorganisation in cell cultures from patients with collagen VI-related dystrophies
2024Open Access
Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model
Skeletal Muscle·2024· 1 citedOpen Access
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
Molecular Therapy — Nucleic Acids·2023· 8 citedOpen Access
Deletion of exons 45 to 55 in the <i>DMD</i> gene: from the therapeutic perspective to the <i>in vitro</i> model
2023Open Access
Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics
Nucleic Acid Therapeutics·2023· 3 citedOpen Access
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
Nucleic Acid Therapeutics·2022· 72 citedOpen Access
miR-106b is a novel target to promote muscle regeneration and restore satellite stem cell function in injured Duchenne dystrophic muscle
Molecular Therapy — Nucleic Acids·2022· 7 citedOpen Access
Lessons learned from developing an oligonucleotide drug for a rare disease
Elsevier eBooks·2022
Contributors
Elsevier eBooks·2022
Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy
Methods in molecular biology·2022· 9 citedOpen Access
Antisense RNA Therapeutics: A Brief Overview
Methods in molecular biology·2022· 9 citedOpen Access
DMD - BIOMARKERS
Neuromuscular Disorders·2021
Review for "Automated immunofluorescence analysis for sensitive and precise dystrophin quantification in muscle biopsies"
2021Open Access
Sharing “Negative” Results in Neuromuscular Research: A Positive Experience
Journal of Neuromuscular Diseases·2021· 3 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Jennifer E. Morgan(17), Annemieke Aartsma‐Rus(13), Francesco Muntoni(12), Volker Straub(11), Karen Anthony(10), Sebahattin Çirak(9), Michela Guglieri(9), Lucy Feng(9), Caroline A. Sewry(9), Andrea López‐Martínez(9), George Dickson(8), Patricia Soblechero‐Martín(8), Silvia Torelli(6), Steve D. Wilton(6), Maria Kinali(6), Francesco Muntoni(6), Dominic J. Wells(5), Matthew J. A. Wood(5), Kate Bushby(5), Linda Popplewell(5)